Back

Ahmed A. Yameny

Ahmed A. Yameny

Society of Pathological Biochemistry and Haematology, Egypt

Title: Digital Molecular Pathology

Biography

Ahmed A.Yameny is the head of Society of Pathological Biochemistry and Haematology. He is Union chief Medical Laboratory in Egypt, he was the Chairman for five international conferences of medical laboratory and two international conferences of the Society,he is  Expert and medical laboratory consultant. He is chief editor Journal of Bioscience and Applied Research (www.jbaar.org), he is a Doctor of Microbiology, high diplomas in (1- bacteriology 2-Public health of parasitology and medical entomology 3-Analytical Biochemistry 4- Haematology 5- Genetic Analysis) , he has a B.Sc. in Biochemistry (Alexandria University in Egypt ), and he has a B.Sc.in Biochemistry/Chemistry(Tanta University in Egypt). 

Abstract

The Molecular Pathology Laboratory offers molecular diagnostic testing for a variety of clinical indications across the health-care continuum, including testing for disease susceptibility, population screening, diagnosis, prognosis, therapeutic decision making, and disease monitoring. Molecular Pathology(MP) is at the heart of modern diagnostics and translational research.It has become evidenthat, to advance in the translation of biomarker discovery into diagnostic  and therapeutic application , the purpose of this article is to advance MP into Digital Molecular Pathology(DMP) ,depending on known biomarkers especially miRNA and proteomics,to resolve  many of the demands in the clinical laboratory , as screening for cancer , endemic or rare virus infection and biological war. We would like to suggest an integrated model of DMP, from biomarkers to form  two stepes of diagnosis and two stepes of treatment,the first step for fast diagnosis and fast therapy to stop spreading of disease, the secod step for complete diagnosis and effectiveness treatment,  many biomarkers were discovered so must divided into groups, DMP can allow facilities to outsource all or a portion of the demands data such as cloud computing, bioinformatics pipelines, variant data management, and knowledge curation. Exchange of electronic molecular data allows laboratories to perform validation of rare diseases using foreign data, check the accuracy of their test results against benchmarks.